Lung shunt fraction calculations before Y-90 transarterial radioembolization: Comparison of accuracy and clinical significance of planar scintigraphy and SPECT/CT - 30/03/23
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Highlights |
• | Lung shunt fraction is better estimated using single-photon emission computerized tomography (SPECT) computed tomography (CT) than using planar scintigraphy. |
• | A significant percentage of patients with lung shunt fraction ≥ 7.5% at planar scintigraphy would benefit of SPECT/CT in terms of avoiding dose reduction or treatment cancelation. |
• | For various subgroups of yttrium-90 treatments, such as hemiliver and selective deliveries or treatment of hepatocellular carcinoma or metastatic disease, planar scintigraphy results in significantly greater overestimation of the realized lung shunt fraction compared to SPECT/CT. |
Abstract |
Purpose |
To determine the accuracy and clinical significance of planar scintigraphy lung shunt fraction (PLSF) and single-photon emission computerized tomography (SPECT) computed tomography (CT) lung shunt fraction (SLSF) before Y-90 transarterial radioembolization.
Materials and methods |
Seventy patients (46 men, 24 women; mean age, 64 ± 9.5 [SD] years) who underwent 83 treatments with Y-90 transarterial radioembolization for primary or secondary malignancies of the liver with a PLSF ≥ 7.5% were retrospectively evaluated. The patients mapping technetium 99 m (Tc-99 m) macroaggregated albumin (MAA) PLSF and SLSF were calculated and compared to the post Y-90 delivery SLSF. A model using modern dose thresholds was created to identify patients who would require dose reduction due to a lung dose ≥ 30 Gy, with patients who required >50% dose reduction considered to be delivery cancelations.
Results |
A significant difference was found between mean PLSF (14.7 ± 11.6 [SD]%; range: 7.5–84.1%) and mean SLSF (8.7 ± 8.5 [SD]%; range: 1.7–73.5) (P < 0.001). The mean realized LSF (7.1 ± 3 [SD]%; range:1.5–17.6) was significantly less than the PLSF (P <0.001) but not the SLSF (P = 0.07). PLSF significantly overestimated the realized LSF by more than the SLSF (8.5 ± 5.3 [SD] % [range: -0.1–21.7] vs. 0.8 ± 3.6 [SD] % [range: -5–13.2], respectively) (P < 0.001). Based on the clinical significance model, 20 patients (20/83, 24.1%) would have required dose reduction or cancelation when using PLSF but would not require even a dose reduction when using the SLSF. Significantly more deliveries would have been be canceled if PLSF was used as compared to SLSF (22/83 [26.5%] vs. 6/83 [7.2%], respectively) (P < 0.001).
Conclusion |
SLSF is significantly more accurate at predicting realized LSF than PLSF and this difference is of clinical significance in a number of patients with a PLSF ≥ 7.5%.
El texto completo de este artículo está disponible en PDF.Keywords : Dosimetry, Hepatocellular carcinoma, Lung shunt fraction, Transarterial radioembolization
Abbreviations : Y-90, CBCT, CT, LSF, HCC, IQR, MAA, MIRD, PLSF, ROI, SD, SLSF, SPECT, TARE, Tc-99 m
Esquema
Vol 104 - N° 4
P. 185-191 - avril 2023 Regresar al número
Artículo precedente
- Acquisition time reduction of diffusion-weighted liver imaging using deep learning image reconstruction
- Saif Afat, Judith Herrmann, Haidara Almansour, Thomas Benkert, Elisabeth Weiland, Thomas Hölldobler, Konstantin Nikolaou, Sebastian Gassenmaier
- Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis
- Christophe Cassinotto, Erika Nogue, Quentin Durand, Fabrizio Panaro, Eric Assenat, Anthony Dohan, Nicolas Malafaye, Boris Guiu, Nicolas Molinari
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.